KZIA Stock Analysis: Buy, Sell, or Hold?
KZIA - Kazia Therapeutics Limited American Depositary Shares
$10.95
-0.84 (-7.12%)
▼
5d:
-9.95%
30d:
-14.72%
90d:
+24.72%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Feb 06, 2026
0d
Get Alerted When KZIA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KZIA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KZIA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KZIA is currently trading at $10.95, which is considered oversold relative to its 30-day fair value range of $12.13 to $13.83.
Technical Outlook: Technically, KZIA is in a strong uptrend. The price is currently testing key support at $10.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.40 (+95.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KZIA is in a strong uptrend. The price is currently testing key support at $10.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.40 (+95.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$12.13 -
$13.83
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- BULLISH: Trading 95.5% below Wall St target ($21.40)
- CAUTION: Recommendation downgraded due to -10.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$12.13 -
$13.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$10.67
Resistance Level
$14.07
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-640.35
Wall Street Target
$21.40
(+95.5%)
Revenue Growth (YoY)
312.4%
Share & Embed Analysis
Last updated: June 03, 2026 8:35 PM ET
Data refreshes hourly during market hours. Next update: 9:35 PM
Data refreshes hourly during market hours. Next update: 9:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KZIA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |
